BackIntellia Therapeutics Overview
Intellia Therapeutics Inc

Intellia Therapeutics Target Price

Analysts' 12-month price predictions for NTLA.

Share Price

$8.28

Average Target Price

$17.50111.4% upside

2 analysts in the last 4 months

High: $26 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2025-02-28Goldman Sachs$98.7% upsideOpen
2025-02-28Barclays$26214% upsideOpen
2024-11-11OppenheimerJay Olson$60624.6% upsideOpen
2024-10-24Robert W. BairdJack Allen$18117.4% upsideOpen
2024-08-09RBC CapitalLuca Issi$54552.2% upsideOpen
2024-06-24Stifel NicolausDae Gon Ha$80866.2% upsideOpen
2024-06-24Robert W. BairdJack Allen$24189.9% upsideOpen
2024-05-10BMO CapitalKostas Biliouris$70745.4% upsideOpen
2023-02-01Cantor Fitzgerald$67709.2% upsideOpen
2023-01-04Wells Fargo$1201349.3% upsideOpen
2022-12-06Credit Suisse$88962.8% upsideOpen
2022-12-02Leerink Partners$86938.6% upsideOpen
2022-11-15Chardan Capital$1291458% upsideOpen
2022-08-05Leerink Partners$1521735.7% upsideOpen
2022-08-05Chardan Capital$1461663.3% upsideOpen
2022-06-16BMO CapitalKostas Biliouris$54552.2% upsideOpen
2022-05-09JMP Securities$1101228.5% upsideOpen
2022-05-09Raymond JamesSteven Seedhouse$1051168.1% upsideOpen
2022-05-06Credit Suisse$981083.6% upsideOpen
2022-02-24RBC CapitalLuca Issi$1501711.6% upsideOpen
2022-02-18William BlairRaju Prasad$1441639.1% upsideOpen
2022-02-15Truist FinancialJoon Lee$1601832.4% upsideOpen
2022-02-03WedbushDavid Nierengarten$1081204.3% upsideOpen
2022-02-03Piper SandlerSwapnil Malekar$1711965.2% upsideOpen
2021-11-16Roth CapitalAnthony Butler$1802073.9% upsideOpen
2021-08-06Goldman SachsSalveen Richter$2522943.5% upsideOpen
2021-08-06Raymond JamesSteven Seedhouse$1812086% upsideOpen
2021-08-05BarclaysGena Wang$2072400% upsideOpen
2021-06-22JefferiesMaury Raycroft$1091216.4% upsideOpen